StageZero Life Sciences Ltd (SZLS) - Total Assets
Based on the latest financial reports, StageZero Life Sciences Ltd (SZLS) holds total assets worth CA$580.75K CAD (≈ $420.11K USD) as of September 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See SZLS total equity for net asset value and shareholders' equity analysis.
StageZero Life Sciences Ltd - Total Assets Trend (1998–2022)
This chart illustrates how StageZero Life Sciences Ltd's total assets have evolved over time, based on quarterly financial data.
StageZero Life Sciences Ltd - Asset Composition Analysis
Current Asset Composition (December 2022)
StageZero Life Sciences Ltd's total assets of CA$580.75K consist of 38.0% current assets and 62.0% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 2.2% |
| Accounts Receivable | CA$31.24K | 4.5% |
| Inventory | CA$95.62K | 13.7% |
| Property, Plant & Equipment | CA$434.44K | 62.0% |
| Intangible Assets | CA$0.00 | 0.0% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (1998–2022)
This chart illustrates how StageZero Life Sciences Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see StageZero Life Sciences Ltd market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: StageZero Life Sciences Ltd's current assets represent 38.0% of total assets in 2022, a decrease from 60.1% in 1998.
- Cash Position: Cash and equivalents constituted 2.2% of total assets in 2022, down from 57.4% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1998.
- Asset Diversification: The largest asset category is property, plant & equipment at 62.0% of total assets.
StageZero Life Sciences Ltd Competitors by Total Assets
Key competitors of StageZero Life Sciences Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Eurofins-Cerep SA
PA:ALECR
|
France | €84.58 Million |
|
Inoviq Ltd
AU:IIQ
|
Australia | AU$24.52 Million |
|
Bcal Diagnostics Ltd
AU:BDX
|
Australia | AU$7.17 Million |
|
Imagion Biosystems Ltd
AU:IBX
|
Australia | AU$932.48K |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$510.21 Million |
StageZero Life Sciences Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.02 | 0.04 | 0.19 |
| Quick Ratio | 0.02 | 0.03 | 0.14 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$-10.09 Million | CA$-7.98 Million | CA$-3.45 Million |
StageZero Life Sciences Ltd - Advanced Valuation Insights
This section examines the relationship between StageZero Life Sciences Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.94 |
| Latest Market Cap to Assets Ratio | 5.10 |
| Asset Growth Rate (YoY) | -93.4% |
| Total Assets | CA$700.65K |
| Market Capitalization | $3.58 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values StageZero Life Sciences Ltd's assets at a significant premium (5.10x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: StageZero Life Sciences Ltd's assets decreased by 93.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for StageZero Life Sciences Ltd (1998–2022)
The table below shows the annual total assets of StageZero Life Sciences Ltd from 1998 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-12-31 | CA$700.65K ≈ $506.84K |
-93.42% |
| 2021-12-31 | CA$10.65 Million ≈ $7.70 Million |
+25.13% |
| 2020-12-31 | CA$8.51 Million ≈ $6.15 Million |
+333.01% |
| 2019-12-31 | CA$1.96 Million ≈ $1.42 Million |
-20.96% |
| 2018-12-31 | CA$2.49 Million ≈ $1.80 Million |
-7.71% |
| 2017-12-31 | CA$2.69 Million ≈ $1.95 Million |
-21.74% |
| 2016-12-31 | CA$3.44 Million ≈ $2.49 Million |
+501.57% |
| 2015-12-31 | CA$572.14K ≈ $413.88K |
-80.48% |
| 2014-12-31 | CA$2.93 Million ≈ $2.12 Million |
-2.09% |
| 2013-12-31 | CA$2.99 Million ≈ $2.17 Million |
-70.19% |
| 2012-12-31 | CA$10.04 Million ≈ $7.26 Million |
+146.56% |
| 2011-12-31 | CA$4.07 Million ≈ $2.95 Million |
-18.49% |
| 2010-12-31 | CA$5.00 Million ≈ $3.61 Million |
-21.45% |
| 2009-12-31 | CA$6.36 Million ≈ $4.60 Million |
+6.20% |
| 2008-12-31 | CA$5.99 Million ≈ $4.33 Million |
-68.54% |
| 2007-12-31 | CA$19.03 Million ≈ $13.77 Million |
-10.18% |
| 2006-12-31 | CA$21.19 Million ≈ $15.33 Million |
+141.43% |
| 2005-12-31 | CA$8.78 Million ≈ $6.35 Million |
-33.24% |
| 2004-12-31 | CA$13.15 Million ≈ $9.51 Million |
+109.42% |
| 2003-12-31 | CA$6.28 Million ≈ $4.54 Million |
+204.11% |
| 2002-12-31 | CA$2.06 Million ≈ $1.49 Million |
-15.76% |
| 2001-12-31 | CA$2.45 Million ≈ $1.77 Million |
+2.13% |
| 2000-12-31 | CA$2.40 Million ≈ $1.74 Million |
+6176.70% |
| 1999-12-31 | CA$38.23K ≈ $27.65K |
-77.27% |
| 1998-12-31 | CA$168.21K ≈ $121.68K |
-- |
About StageZero Life Sciences Ltd
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers fr… Read more